Biote Corp. Files 8-K on Officer Changes and Financials

Ticker: BTMD · Form: 8-K · Filed: Jan 30, 2025 · CIK: 1819253

Sentiment: neutral

Topics: officer-change, director-election, financials, regulation-fd

TL;DR

Biote Corp. 8-K: Exec changes, board elections, and financial updates filed Jan 30.

AI Summary

Biote Corp. filed an 8-K on January 30, 2025, reporting on the departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements. The filing also covers Regulation FD disclosures and financial statements/exhibits, with the earliest event reported as January 29, 2025. Biote Corp., formerly Haymaker Acquisition Corp. III, is incorporated in Delaware and based in Irving, Texas.

Why It Matters

This 8-K filing provides crucial updates on Biote Corp.'s executive and board composition, as well as regulatory disclosures, which can impact investor confidence and strategic direction.

Risk Assessment

Risk Level: medium — Filings related to executive changes, board composition, and financial statements can indicate significant internal shifts or regulatory compliance issues that may affect the company's stability and future performance.

Key Numbers

Key Players & Entities

FAQ

What specific officer positions were affected by the changes reported in this 8-K?

The filing indicates changes related to 'Departure of Directors or Certain Officers' and 'Appointment of Certain Officers', but does not specify the exact positions in the provided text.

Were there any new directors elected to the Biote Corp. board?

Yes, the filing lists 'Election of Directors' as an item information, indicating new board members may have been elected.

What is the primary business of Biote Corp. according to its SIC code?

Biote Corp.'s Standard Industrial Classification (SIC) code is 2833, which corresponds to 'MEDICINAL CHEMICALS & BOTANICAL PRODUCTS'.

When did Biote Corp. change its name from Haymaker Acquisition Corp. III?

The date of the name change from Haymaker Acquisition Corp. III to biote Corp. was July 27, 2020.

What type of compensatory arrangements are mentioned in the filing?

The filing mentions 'Compensatory Arrangements of Certain Officers' as an item information, suggesting details about executive compensation are included.

Filing Stats: 1,845 words · 7 min read · ~6 pages · Grade level 11.3 · Accepted 2025-01-30 16:45:20

Key Financial Figures

Filing Documents

From the Filing

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 29, 2025 biote Corp. (Exact name of registrant as specified in its charter) Delaware 001-40128 85-1791125 (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.) 1875 W. Walnut Hill Ln #100 Irving , Texas 75038 (Address of principal executive offices, including zip code) (844) 604-1246 (Registrant's telephone number, including area code) (Former name or former address, if changed since last report) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbols Name of each exchange on which registered Class A common stock, par value $0.0001 per share BTMD The Nasdaq Stock Market LLC Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencements communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (240.12b-2 of this chapter). Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Item5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Resignation of Teresa S. Weber On January 29, 2025, the Board of Directors (the "Board") of biote Corp. (the "Company") accepted the resignation of Teresa S. Weber, the Company's Chief Executive Officer, from all positions she holds with the Company, including stepping down from the Board, effective as of February 1, 2025 (the "Effective Date"). Such resignation did not result from any disagreement with the Company on any matter relating to the Company's operations, policies or practices. Appointment of Bret Christensen Concurrently, the Board, upon the recommendation of the Nominating and Corporate Governance Committee, appointed Bret Christensen as Chief Executive Officer (principal executive officer) of the Company and as a member of the Board to fill the vacancy created by Ms. Weber's resignation, effective as of the Effective Date. Mr. Christensen will serve as a Class III director until the Company's 2025 Annual Meeting of Stockholders and until such time as his successor is duly elected and qualified, or until his earlier death, resignation or removal. Mr. Christensen, age 54, joins the Company from DermTech, Inc. (OTC: DMTKQ), where he served as the President, Chief Executive Officer and director from May 2023 to September 2024. From May 2017 to May 2023, Mr. Christensen was the Chief Commercial Officer of Insulet Corporation (Nasdaq: PODD), where he oversaw sales growth from approximately $367 million to $1.1 billion. From August 2013 to May 2017, Mr. Christensen served as general manager of Preventive Care at Myriad Genetics, Inc. (Nasdaq: MYGN). Prior to Myriad Genetics, Mr. Christensen held several executive positions at Hologic, Inc. (Nasdaq: HOLX), including vice president of sales and marketing of its Gynecologic Surgical Products division. Prior to Hologic, Inc., Mr. Christensen led key market development and sales teams at Cytyc Corporation. Mr. Christensen has served as a member of the board of directors of Axena Health since May 2024 and as the chairman since October 2024. Mr. Christensen earned a B.S. in Business Management from Utah Valley University and an MBA from the University of Utah. We believe Mr. Christensen's extensive experience in women's health and the broader healthcare sector qualifies him to serve as a member of the Board. Offer Letter with Bret Christensen In connection with his appointment as Chief Executive Officer, the Company entered into an offer letter with Mr. Christensen, dated as of January 29, 2025 (the "Offer Letter"). The Offer Letter provides for Mr. Christensen's at-will employment and his duties as the Chief Executive Officer commencing on February 1, 2025. Under the terms of the Offer Letter, Mr. Christensen will receive an annual base salary of $700,000 per year and will be eligible to: (i) receive an an

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing